Epidemiology Unit, Agency for Health Protection (ATS) of Milan, C.so Italia, 19, 20122 Milano, Milan, (MI), Italy.
General Directorate, Agency for Health Protection (ATS) of Milan, Milan, Italy.
BMC Endocr Disord. 2020 May 19;20(1):72. doi: 10.1186/s12902-020-0546-1.
We quantified, among diabetic adults, the frequency, costs, and factors associated with visits to the emergency department (EDs) and subsequent hospitalizations for acute hypoglycaemic and hyperglycaemic events.
We included adults with diabetes residing in the Milan Agency for Health Protection between 2015 and 2017. From healthcare databases, we identified demographic variables, comorbidities, type of treatment, insulin treatment duration, previous ED attendances for acute glycaemic events, and two indicators of glycaemic monitoring. Using a validated ICD-9-CM coding algorithm, we identified all ED attendances for acute glycaemic events from the ED database and calculated their incidence. We computed the direct costs from health databases and presented them as average annual mean costs for those having had at least an ED attendance. The analysis of the association between the number of ED attendances and potential determinants was performed using zero-inflated negative binomial regression models. These two-part models concomitantly estimate two sets of parameters: the odds-ratios (ORs) of having no attendances and the incidence rate ratios (IRRs) of attendance.
The cohort included 168,285 subjects, 70% of subjects were older than 64 years, 56% were males, and 26% were treated with insulin. The incidence of acute glycaemic events for those attending the ED was 7.0 per 1000 patient-years, followed by hospitalization 26.0% of the time. The total annual direct cost for ED attendances due to acute glycaemic events was 174,000 €. Type of antidiabetic treatment had the strongest association with ED attendances for hypoglycaemia. Patients assuming insulin only had a lower probability of having no attendances (OR compared to those who assumed non-insulin antidiabetic drugs =0.01, 95% CI = 0.00-0.02). These patients also had the highest rate of hyperglycaemic episodes (IRR = 7.7, 95% CI = 5.1-11.7 for insulin only vs. non-insulin antidiabetic drugs). Subjects having had a previous episode of the same type leading to an ED visit had a higher rate of subsequent attendances (IRR for hypoglycaemia = 5.3, 95% CI = 3.9-7.3 and IRR for hyperglycaemia = 3.7, 95% CI = 1.3-10.2).
Insulin treatment and having had a prior acute glycaemic event leading to an ED visit were major predictors of ED attendance for hyper and hypoglycaemia in a population of adults with diabetes.
我们在糖尿病成年患者中量化了因急性低血糖和高血糖事件而前往急诊部(ED)就诊和随后住院的频率、费用和相关因素。
我们纳入了 2015 年至 2017 年期间居住在米兰卫生保护局的糖尿病成年患者。我们从医疗保健数据库中获取了人口统计学变量、合并症、治疗类型、胰岛素治疗持续时间、以前因急性血糖事件而就诊的 ED 就诊情况以及血糖监测的两个指标。我们使用经过验证的 ICD-9-CM 编码算法,从 ED 数据库中确定了所有因急性血糖事件而就诊的 ED 就诊情况,并计算了其发生率。我们从健康数据库中计算了直接费用,并以至少有一次 ED 就诊的患者的平均年平均费用表示。使用零膨胀负二项回归模型分析了 ED 就诊次数与潜在决定因素之间的关联。这些两部分模型同时估计了两组参数:无就诊的优势比(OR)和就诊的发病率比(IRR)。
该队列包括 168285 名患者,70%的患者年龄大于 64 岁,56%为男性,26%接受胰岛素治疗。因 ED 就诊的急性血糖事件发生率为每 1000 患者年 7.0 例,随后住院的比例为 26.0%。因急性血糖事件而导致 ED 就诊的直接年度总费用为 174,000 欧元。抗糖尿病治疗类型与低血糖症的 ED 就诊次数有最强的关联。仅使用胰岛素的患者无就诊的可能性较低(与使用非胰岛素抗糖尿病药物的患者相比,OR=0.01,95%CI=0.00-0.02)。这些患者也有最高的高血糖发作率(IRR=7.7,95%CI=5.1-11.7,仅胰岛素与非胰岛素抗糖尿病药物)。以前有过同样类型导致 ED 就诊的发作的患者,随后就诊的比例更高(低血糖发作的 IRR=5.3,95%CI=3.9-7.3;高血糖发作的 IRR=3.7,95%CI=1.3-10.2)。
在糖尿病成年患者人群中,胰岛素治疗和以前因急性血糖事件导致 ED 就诊是 ED 就诊治疗高血糖和低血糖的主要预测因素。